Belviq Market Withdrawal

Share This Post

Belviq Recall

The pharmaceutical company, Eisai, recently withdrew Belviq (lorcaserin) from the market at the request of federal regulators. Some members of our patient community began taking Belviq off-label, after reports that it potentially helped with seizure control, even though it received FDA approval as a weight-loss drug.

The abrupt withdrawal of Belviq has caused concerns and challenges for patients with Dravet syndrome who take Belviq off-label. Eisai has established a centralized Expanded Access program, eliminating the need for physicians to submit their own INDs. Neurologists should contact Eisai at esi_medinfo@eisai.com for assistance obtaining access for their patients.

Read more about off-label use and the market withdrawal of Belviq on this recent Decoding Dravet blog post.

medicine, treatment, pill

Get updates About our Most Recent News & Events

More Recent News

Scroll to Top